contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


ascelia-pharma-announces-acceptance-of-orviglance-data-for-oral-presentation-at-the-annual-radiology-congress-esgar-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Ascelia Pharma er et svensk biotek selskab med fokus på behandling af sjældne kræftsygedomme. De udvikler og markedsfører nye lægemidler, hvor der er behov for bedre behandlingsmuligheder eller hvor der ikke findes muligheder for behandling i dag, og de har en klar go-to-market strategi. Ascelia Pharma har to kandidater i pipelinen, Orviglance og Oncoral. Orviglance er et nyt kontrastmiddel til MR-scanning, og udviklet til at forbedre opdagelsen og visualiseringen af fokale leverlæsioner(Inklusiv levermetastaser – og primære tumorer) hos patienter med nedsat lever funktion. Oncoral er en tablet med en potent anti-tumor effekt, der indtages på daglig basis. Oncoral har vist god effekt ved kræftformer der er svære at behandle, og en bedre virkning/bivirkningsprofil for patienten sammenlignet med intravenøs behandlinger med høj dose udført på et hospital.
 
Ascelia Pharma er noteret på Nasdaq Small Cap Stockholm med ticker ACE.

Den har været på observationslisten. Aktien styrtede for et par år siden, da to gradere havde fortolket de samme MR-billeder forskelligt på forskellige tidspunkter. Fortolkningerne måtte laves om. Firmaet røg ind i en svær spiral med finansieringen i post-covid-krakket. Dette er blot fra hukommelsen. Men produktet er meget niche. For niche til mig. Svært at vurdere, hvor stort markedet er. Og hvor godt produktet egentlig er. Desuden er der så knap/svært tilgængelig information på firmaets egne sider, at jeg springer over.

Ascelia har, ligesom mange andre biotekselskaber, oplevet en total kapitulation, når det kommer til aktiekursen. Det skal dog bemærkes, at en FDA-godkendelse er lige om hjørnet, og selvom der er tale om en penny-aktie, siger det ikke i sig selv noget om fremtiden. Det lyder i udgangspunktet ret interessant, hvis virksomheden kan gøre det lettere at opdage og behandle metastaser i leveren.                   ascelia.com              About us – ASCELIA    Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medic ...

Lad os også åbne en tråd for dette. Ascelia er en virksomhed fra Sverige, der specialiserer sig i kræftdiagnostik og -behandling. Virksomhedsside: Ascelia Pharma - Inderes Investeringsanalyse: https://www.inderes.fi/fi/ascelia-pharma-investment-case-24-march-2022-hc-andersen-capital

Ascelia Pharma

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an evaluation of the detection...

<div class="mfn-preamble">Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an evaluation of the detection of focal liver lesions with Orviglance contrast agent from two phase 2 studies has been accepted for oral presentation at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting, taking place 9-12 June in Montpellier, France.</div><div class="mfn-body">The abstract titled “Diagnostic Value of Manganese-Based Contrast Agent (ACE-MBCA) vs Unenhanced MRI in Liver Lesion Detection: Re-analysis of STAR Study Images from Two Phase II Clinical Trials”, demonstrated that Orviglance significantly improves the detection of focal liver lesions compared to unenhanced MRI. The findings underline the potential of Orviglance as a new contrast agent for liver MRI.“We are excited that an abstract with Orviglance data has been selected for oral presentation at ESGAR, one of the leading global forums for innovation in gastrointestinal and abdominal imaging. This recognition highlights the growing scientific interest in manganese-based contrast agents”, says Andreas Norlin, CSO of Ascelia Pharma.Presenting author: Dr. D. Geisel (Charité - Universitätsmedizin Berlin, Germany) Timing of presentation: 9 June 2026, 10:00 - 10:30 CET &nbsp;Ascelia Pharma has submitted the New Drug Application (NDA) for Orviglance to the US Food and Drug Administration (FDA)&nbsp;with expected approval date of 3 July 2026.</div><div class="mfn-footer mfn-5c7f03d9b448">Contacts<hr>Magnus Corfitzen, CEO Email:&nbsp;<a href="mailto:moc@ascelia.com" rel="noopener">moc@ascelia.com</a> Tel: +46 735 179 118Anton Hansson, CFO Email:&nbsp;<a href="mailto:anton.hansson@ascelia.com" rel="noopener">anton.hansson@ascelia.com</a> Tel: +46 735 179 113This information was submitted for publication, through the agency of the contact persons set out above.</div><div class="mfn-footer mfn-1f353253d071">About us<hr>Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit&nbsp;<a href="http://www.ascelia.com/" rel="noopener">http://www.ascelia.com.</a> About Orviglance Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results. The New Drug Application (NDA) has been submitted to the FDA.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/69cf9b78-a193-4915-b01f-cede766a676d/ascelia-pharma-announces-acceptance-of-orviglance-data-for-oral-presentation-at-the-annual-radiology-congress-esgar-2026.pdf" rel="noopener">ASCELIA PHARMA ANNOUNCES ACCEPTANCE OF ORVIGLANCE DATA FOR ORAL PRESENTATION AT THE ANNUAL RADIOLOGY CONGRESS ESGAR 2026</a></div>

ASCELIA PHARMA ANNOUNCES ACCEPTANCE OF ORVIGLANCE DATA FOR ORAL PRESENTATION AT THE ANNUAL RADIOLOGY CONGRESS ESGAR 2026

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Nordea Bank

Aktionær i Nordea? Det er nemmere end nogensinde at deltage i Nordeas generalforsamling takket være nyt digitalt setup

Return on capital (ROE, ROI, ROIC, RONIC)

Balance sheet, debt leverage and risks